11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse

11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse

Functional disorders of the pelvic floor frequently coexist, impairing quality of life and presenting complex diagnostic and reconstructive challenges. Overactive bladder (OAB) syndrome, Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC), and pelvic organ prolapse (POP) share anatomical, neuromuscular, and physiological links that require structured, guideline-adherent management.

---

1. Overactive Bladder (OAB) Syndrome: Definition & Diagnostic Workup

According to the International Continence Society (ICS), Overactive Bladder (OAB) is defined as:

Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.

• OAB Wet vs OAB Dry: Approximately one-third of OAB patients exhibit involuntary leakage (OAB wet), whereas two-thirds experience severe urgency and frequency without leakage (OAB dry).
• Urgency is the Sine Qua Non: Urgency—a sudden, compelling desire to void that is difficult to defer—is the cardinal symptom that drives frequency and nocturia.

Mandatory Initial Assessment

1. Focused History & 3-Day Bladder Diary: Quantify frequency, nocturia, volumes, fluid intake and urgency. Interpret counts with age, intake and bother rather than diagnosing OAB from a fixed normal daily/nightly cutoff.
2. Urinalysis: Perform initially; obtain culture when infection is suspected or the clinical setting warrants it.
3. Post-Void Residual (PVR) Measurement: Excludes urinary retention and overflow states prior to administering antimuscarinic or neuromodulating agents.
4. Red Flag Recognition: Microscopic or gross hematuria, refractory dysuria, recurrent culture-negative pyuria, or pelvic pain requires appropriate further assessment for malignancy, stones or other pathology. Select cystoscopy and imaging according to the findings and risk rather than automatically performing both for every symptom.

---

2. OAB Management Options

┌────────────────────────────────────────────────────────────────────────┐
│                     OAB MANAGEMENT OVERVIEW                           │
├────────────────────────────────────────────────────────────────────────┤
│  TIER 1: CONSERVATIVE & BEHAVIORAL                                     │
│  • Fluid moderation (1.5–2.0 L/day)  • Bladder training (scheduled)    │
│  • Caffeine / alcohol reduction      • Pelvic floor muscle training    │
│  • Supervised weight loss (BMI >30)  • Urge suppression maneuvers      │
├────────────────────────────────────────────────────────────────────────┤
│  TIER 2: PHARMACOTHERAPY                                               │
│  • Antimuscarinics (solifenacin, tolterodine, fesoterodine, trospium)  │
│  • Beta-3 Agonists (mirabegron 50 mg, vibegron 75 mg)                  │
│  • Combination Therapy (Antimuscarinic + Beta-3 Agonist)               │
├────────────────────────────────────────────────────────────────────────┤
│  TIER 3: SPECIALIZED REFRACTORY INTERVENTIONS                          │
│  • Intravesical OnabotulinumtoxinA (100 U; ~5% CISC risk)              │
│  • Sacral Neuromodulation (SNM / InterStim; S3 root stimulation)       │
│  • PTNS is also an earlier non-drug option, according to preference. │
└────────────────────────────────────────────────────────────────────────┘

These categories organize study, rather than impose a mandatory sequence. EAU offers PTNS as an option for OAB/UUI; it need not await failure of every drug. Choose treatment with the patient according to benefit, adverse effects and practical burden.

Tier 1: Conservative & Behavioral Therapies

• Fluid Intake Optimization: Moderating excessive consumption to 1.5–2.0 L/day; restricting fluid intake 2 to 3 hours prior to sleep reduces nocturia.
• Dietary Modification: Elimination of caffeine, alcohol, carbonated beverages, and artificial sweeteners, which irritate the urothelium.
• Bladder Retraining: Structured, timed voiding with progressive interval expansion (e.g., increasing voiding intervals by 15–30 minutes weekly) combined with active urge-suppression maneuvers (distraction, slow diaphragmatic breathing, pelvic floor contraction).
• Supervised Weight Loss: Highly effective in overweight individuals; reduces intra-abdominal baseline pressures.

Tier 2: Pharmacotherapy

Antimuscarinics (Anticholinergics)

• Mechanism: Competitive antagonists of muscarinic acetylcholine receptors ($M_2$ and $M_3$) on detrusor myocytes and suburothelial sensory afferents. Suppress involuntary detrusor contractions during the storage phase, increase bladder capacity, and delay the first desire to void.
• Agents: Solifenacin, tolterodine, fesoterodine, oxybutynin, darifenacin ($M_3$-selective), and trospium chloride.
• The Blood-Brain Barrier & Cognitive Safety:
  • Antimuscarinics differ in CNS penetration and cognitive evidence. Oral oxybutynin is particularly concerning in older people. Consider total anticholinergic burden and monitor cognition; observational dementia associations do not establish that every drug causes dementia.
  • Trospium Chloride: A quaternary ammonium compound with high polarity and low lipid solubility. It has low CNS penetration and may be considered when an antimuscarinic is needed, but constipation and other antimuscarinic effects still matter; it is not automatically the best choice for every cognitively impaired patient.
• Contraindications: Untreated narrow-angle glaucoma, myasthenia gravis, severe gastrointestinal retention / toxic megacolon, and urinary retention. A high PVR requires clinical assessment; do not import the male-LUTS 150-mL precaution as a universal female contraindication threshold.
• Adverse Effects: Dry mouth (xerostomia), constipation, blurred vision, dyspepsia, somnolence.

Beta-3 Adrenergic Agonists

• Mechanism: Direct stimulation of $\beta_3$-adrenergic receptors in detrusor smooth muscle activates adenylyl cyclase, increases intracellular cyclic adenosine monophosphate (cAMP), and induces active detrusor relaxation during the bladder storage phase without decreasing voiding contraction amplitude.
• Agents:
  • Mirabegron (50 mg once daily): Has broadly comparable symptom efficacy while avoiding antimuscarinic burden and generally causing less dry mouth. Adverse effects and individual comorbidities still require assessment. Absolute Contraindication: Severe uncontrolled hypertension (systolic BP $\ge$ 180 mmHg or diastolic BP $\ge$ 110 mmHg). Baseline blood pressure must be evaluated and monitored periodically.
  • Vibegron (75 mg once daily): Highly selective $\beta_3$ agonist with negligible CYP2D6 inhibition, no requirement for dose adjustment in renal impairment (eGFR $\ge$ 15 mL/min), and no observed clinical blood pressure elevation.
• Combination Therapy: Combining an antimuscarinic (e.g., solifenacin 5 mg) with a $\beta_3$-agonist (e.g., mirabegron 50 mg) targets two molecular pathways and can improve symptoms beyond monotherapy, but monitor tolerability and emptying; combination does not eliminate dry mouth, constipation or retention risk.

Tier 3: Specialized Interventions for Refractory OAB

Intravesical OnabotulinumtoxinA (Botox)

• Approved Dose for Idiopathic OAB: 100 Units (diluted in 10 mL normal saline, injected as 0.5–1.0 mL aliquots across 10 to 20 intradetrusor sites via flexible or rigid cystoscopy, typically sparing the trigone).
• Mechanism of Action: The heavy chain binds with high affinity to SV2 receptors on presynaptic parasympathetic nerve terminals. Following receptor-mediated endocytosis, the zinc-dependent light chain cleaves SNAP-25 (synaptosome-associated protein 25), preventing SNARE complex assembly and blocking presynaptic vesicular exocytosis of acetylcholine. It also downregulates sensory purinergic ($P2X_3$) and capsaicin ($TRPV_1$) receptors in suburothelial C-fibers.
• Clinical Dynamics: Onset of action within 5 to 7 days; therapeutic duration lasts 6 to 9 months, requiring maintenance reinjections.
• Complications & Prerequisite Counseling:
  • Elevated post-void residual and the need for Clean Intermittent Self-Catheterization (CISC) occurs in approximately 5% to 6% of idiopathic OAB patients.
  • Uncomplicated bacteriuria or symptomatic UTI occurs in 15% to 20%.
  • Before Injection: Counsel about possible prolonged retention and ensure willingness and a feasible plan for intermittent catheterization if required.

Sacral Neuromodulation (SNM / InterStim)

• Mechanism: Low-amplitude chronic electrical stimulation of the S3 sacral nerve root modulates spinal afferents, resetting aberrant somato-visceral autonomic reflex pathways in the sacral cord and pontine micturition center.
• Two-Stage Implantation:
  • Stage 1 (Test Phase): Percutaneous nerve evaluation (PNE) or placement of a quadripolar tined lead into the S3 sacral foramen under fluoroscopic guidance. Verified intraoperatively by motor response (plantar flexion of the great toe and contraction of the anal sphincter ["bellows sign"]) and sensory response (perineal vibration). Symptoms are tracked on a bladder diary for 1 to 2 weeks.
  • Stage 2 (Permanent Implant): If $\ge$ 50% improvement in voiding diary parameters is documented, a permanent subcutaneous implantable pulse generator (IPG) is implanted in the upper buttock.
• Indications: Refractory OAB (wet or dry), non-obstructive chronic urinary retention, and chronic fecal incontinence.

Posterior Tibial Nerve Stimulation (PTNS)

• Modulation of sacral micturition circuits through tibial afferents via a 34-gauge needle inserted 5 cm cephalad to the medial malleolus adjacent to the posterior tibial nerve.
• Standard protocol: 30-minute outpatient stimulation sessions administered weekly for 12 consecutive weeks, followed by monthly maintenance sessions.

---

3. Bladder Pain Syndrome (BPS / Interstitial Cystitis) & Hunner Lesions

Bladder Pain Syndrome (BPS)—historically referred to as Interstitial Cystitis (IC)—is a chronic, debilitating disorder characterized by visceral pelvic pain and profound urinary frequency.

Definition & Diagnostic Criteria

IC/BPS requires bladder-related pain, pressure or discomfort with urinary symptoms, after assessment for infection and other confusable diseases. Pain-driven urgency differs from the compelling desire to void typical of OAB.

The historical ESSIC2008 definition used >6 months; AUA/SUFU uses >6 weeks. The 2026 ESSIC proposal emphasizes clinical symptoms, exclusion of confusable disease, cystoscopy and bladder-centric versus non-bladder-centric phenotyping. Do not label a six-week rule as the ESSIC definition or delay assessment solely to satisfy a historical duration threshold.

• Hallmark Pain Pattern: The discomfort characteristically increases progressively as the bladder fills and is temporarily or partially relieved upon voiding/emptying.

Mandatory Diagnostic Evaluation

1. Exclusion of Confusable Diseases: BPS is fundamentally a diagnosis of exclusion. Mandatory tests include:
   • Midstream Urinalysis & Culture: Assess for bacterial infection; request mycobacterial testing with sterile pyuria or relevant risk. Routine culture does not by itself exclude every fungal/mycobacterial cause.
   • Cystoscopy / Cytology: EAU recommends cystoscopy to subtype bladder pain and exclude confusable disease; use cytology in relevant risk groups. Biopsy suspicious lesions when indicated: negative cytology does not exclude CIS. Age >40 alone is not a universal combined-test rule.
   • Select ultrasound or cross-sectional imaging when clinical findings suggest calculi, masses or upper-tract pathology.
   • Gynecological and neurological evaluation to rule out endometriosis, pelvic inflammatory disease, or pudendal neuralgia.
2. Objective Symptom & Pain Scoring:
   • Visual Analog Scale (VAS) pain score (0–10).
   • O'Leary-Sant Interstitial Cystitis Symptom and Problem Index (ICSI / ICPI): Benchmark validated questionnaire assessing urgency, frequency, nocturia, and pain severity.
   • Pelvic Pain and Urgency/Frequency (PUF) questionnaire.

Cystoscopy with Hydrodistension

Specialist cystoscopy assesses the mucosa and may include hydrodistension/biopsy. The 2026 ESSIC technique uses 60–80 cmH2O and two minutes at capacity, stopping earlier for significant tears or bleeding; the 80-cmH2O/two-minute approach in the case below fits this range:

• Classic Hunner Lesions (Historical ESSIC Type 3; IC/Hunner Lesion Disease):
  • Frequency varies greatly with population and cystoscopy methods; lesions are more common in older patients.
  • Appears as circumscribed, reddened mucosal patches with small vessels radiating toward a central pale scar or fibrin deposit.
  • Upon bladder deflation/decompression following hydrodistension, the lesion demonstrates characteristic mucosal cracking and active "waterfall-like" bleeding.
• Non-Hunner Disease: Normal Mucosa or Glomerulations:
  • Inspection may reveal petechial haemorrhages termed glomerulations, but cystoscopy may also be normal. Historical ESSIC type 1 is normal, type 2 has glomerulations; these are not interchangeable findings.
  • Caveat: Glomerulations are non-specific and can occasionally be observed in asymptomatic controls; therefore, glomerulations alone without typical clinical pain do not establish the diagnosis.
• Historical ESSIC Classification Matrix:
  • Based on cystoscopy finding (1 = normal; 2 = glomerulations; 3 = Hunner lesion) and bladder biopsy finding (A = normal; B = inconclusive; C = inflammatory / mast cell infiltration, intrafascicular fibrosis). For example, Hunner lesions with qualifying inflammatory histology are 3C. These historical codes remain in EAU teaching; the 2026 ESSIC proposal separately emphasizes IC/Hunner lesion disease and bladder-centric/non-bladder-centric phenotypes.

Phenotype-Oriented Treatment

Combine education, behavioural, physical and psychological care with treatments selected for the patient’s phenotype. The following groups summarize options, not a mandatory five-step EAU sequence. Treat Hunner lesions directly when present rather than requiring failure of every preceding group:

┌────────────────────────────────────────────────────────────────────────┐
│                     BPS/IC TREATMENT OPTIONS                          │
├────────────────────────────────────────────────────────────────────────┤
│  LEVEL 1: CONSERVATIVE & PHYSICAL THERAPY                              │
│  • Avoidance of acidic foods, caffeine, alcohol, artificial sweeteners │
│  • Pelvic floor down-training & myofascial release (NO KEGELS)         │
├────────────────────────────────────────────────────────────────────────┤
│  LEVEL 2: ORAL PHARMACOTHERAPY                                         │
│  • Amitriptyline (10–75 mg nightly; central neuromodulation & H1 block)│
│  • Pentosan Polysulfate Sodium (PPS 100 mg TID; proposed GAG support;    │
│    EU-scheduled eye checks for pigmentary maculopathy)    │
│  • Antihistamines (hydroxyzine) • Non-opioid multimodal analgesics    │
├────────────────────────────────────────────────────────────────────────┤
│  LEVEL 3: INTRAVESICAL INSTILLATIONS                                   │
│  • Glycosaminoglycan (GAG) replenishment (hyaluronic acid, chondroitin)│
│  • Intravesical DMSO (dimethyl sulfoxide; local symptom treatment) │
│  • Alkalinized lidocaine + heparin instillations for acute flares      │
├────────────────────────────────────────────────────────────────────────┤
│  LEVEL 4: HUNNER LESION INTERVENTIONS                                  │
│  • Transurethral resection (TUR) or electrocautery / laser fulguration │
│  • Submucosal triamcinolone injection using a specialist protocol    │
├────────────────────────────────────────────────────────────────────────┤
│  LEVEL 5: REFRACTORY SPECIALIST INTERVENTIONS                          │
│  • Intradetrusor OnabotulinumtoxinA (100 U; risk of retention & CISC)  │
│  • Sacral Neuromodulation (SNM)                                        │
│  • Major reconstructive surgery: supratrigonal cystectomy + cysto-     │
│    plasty or total cystectomy with urinary diversion (last resort)     │
└────────────────────────────────────────────────────────────────────────┘

1. Level 1: Conservative & Dietary Modification:
   • Dietary Elimination: Strict avoidance of known urothelial irritants: acidic fruits (citrus, cranberries), tomatoes, coffee/tea (caffeine), carbonated beverages, alcohol, spicy foods, and artificial sweeteners.
   • Pelvic Floor Physical Therapy: Specialized manual therapy aimed at pelvic floor down-training, muscle elongation, and myofascial trigger point release.
   • Crucial Exam Rule: Avoid Kegel strengthening as BPS pain therapy. Assess pelvic-floor tenderness and high tone; relaxation and manual/myofascial treatment are appropriate when these are present.
2. Level 2: Oral Pharmacotherapy:
   • Amitriptyline (10 to 75 mg daily at bedtime):
     • An evidence-supported oral option; select within multimodal care rather than a universal mandatory first drug.
     • Tripartite Mechanism: (1) Central serotonin and norepinephrine reuptake inhibition desensitizes ascending spinal nociceptive pathways; (2) $H_1$-receptor antagonism stabilizes bladder mast cells; (3) mild anticholinergic effects suppress uninhibited detrusor spasms.
     • Adverse Effects: Sedation, weight gain, xerostomia, constipation, cardiac conduction prolongation.
   • Pentosan Polysulfate Sodium (PPS / Elmiron; 100 mg TID):
     • An oral heparin-like polysaccharide proposed to support the urothelial GAG barrier. In the EU, Elmiron is indicated for adults with moderate-to-severe BPS symptoms characterized by glomerulations or Hunner lesions. Reassess benefit at six months and stop if there is no improvement.
     • Critical Board Warning (Pigmentary Maculopathy): Chronic, cumulative long-term use of PPS is linked to a distinctive, vision-threatening drug-induced pigmentary maculopathy. Follow current EU product information: eye examination after six months, then regularly after five years if normal (earlier for visual symptoms); yearly if relevant abnormalities are found. Consider treatment cessation with ophthalmology if abnormal findings arise. Do not describe baseline-plus-annual testing for everyone or immediate cessation in every case as the EU rule.
   • Antihistamines: Hydroxyzine (25–50 mg nightly) is an H1-blocking option used in selected patients; controlled evidence of BPS benefit is inconsistent, so do not promise efficacy based on an allergic history.
   • Analgesics: Multimodal analgesia including paracetamol, NSAIDs, and gabapentin/pregabalin for neuropathic hyperalgesia. Long-term chronic opioid therapy is strongly discouraged.
3. Level 3: Intravesical Instillations:
   • Glycosaminoglycan (GAG) Layer Substitution: Weekly instillations of hyaluronic acid (Cystistat), chondroitin sulfate (Gepan), or fixed combinations (hyaluronic acid + chondroitin sulfate) coat the urothelium and restore the defective mucosal permeability barrier.
   • Dimethyl Sulfoxide (DMSO; 50% solution): Instilled into the bladder for 15–20 minutes every 1 to 2 weeks for 6 cycles. Has proposed anti-inflammatory, analgesic and muscle-relaxant effects; it does not chemically ablate bladder mast cells. Imparts a characteristic garlic-like breath and skin odor for 24–48 hours.
   • Alkalinized Lidocaine & Heparin ("Rescue Cocktail"): Provides immediate temporary local mucosal analgesia and protective barrier coverage for acute exacerbations.
4. Level 4: Endoscopic Management of Hunner Lesions:
   • In patients with documented ulcerative BPS (Hunner lesions), direct endoscopic treatment is the gold standard therapy of choice, offering rapid and profound symptom relief:
   • Transurethral Resection (TUR) / Fulguration: Light electrocautery fulguration (rollerball or bugbee electrode), bipolar resection, or laser vaporization (Nd:YAG, diode) of the entire ulcerated area and its central fibrovascular core.
   • Submucosal Triamcinolone Acetonide Injection: Submucosal injection of triamcinolone into Hunner lesions is an alternative lesion-directed approach. Dose and technique vary; explain that response and duration vary and repeat treatment may be needed.
5. Level 5: Refractory Advanced Interventions:
   • Intradetrusor OnabotulinumtoxinA (100 U): May improve refractory symptoms, often combined with hydrodistension. Counsel about UTI, impaired emptying and possible catheterization; do not assert a universally greater retention risk than in OAB.
   • Sacral Neuromodulation (SNM): May improve refractory urgency and frequency, though pain relief is variable.
   • Major Reconstructive Surgery (Last Resort): Reserved for carefully selected severe refractory disease, after multidisciplinary assessment. A small fibrotic bladder may support selection, but no universal <150–200-mL cutoff determines eligibility. Consists of supratrigonal cystectomy with clam ileocystoplasty bladder augmentation (highly effective in Hunner disease) or total cystectomy with urinary diversion (ileal conduit). Pain may persist after reconstruction or diversion, especially when symptoms are not predominantly bladder-driven; neither success nor failure is determined by Hunner status alone.

---

4. Pelvic Organ Prolapse (POP) & The POP-Q System

Pelvic organ prolapse is the downward herniation of pelvic organs (bladder, uterus, vaginal cuff, bowel) into or beyond the vaginal canal, resulting from attenuation of endopelvic connective tissue and pelvic floor muscular support.

DeLancey Levels of Pelvic Support

• Level I (Suspension): Apical suspension of the uterus and vaginal vault via the cardinal and uterosacral ligament complex to the sacrum and pelvic sidewalls.
• Level II (Lateral Attachment): Mid-vaginal lateral attachment of the pubocervical and rectovaginal fascia to the arcus tendineus fasciae pelvis (ATFP), supporting the bladder and rectum.
• Level III (Distal Fusion): Fusion of the distal third of the vagina to the perineal body, perineal membrane, and levator ani musculature.

The ICS POP-Q Examination System

The Pelvic Organ Prolapse Quantification (POP-Q) system utilizes six defined vaginal points and three additional measurements measured in centimeters relative to the hymenal ring (plane 0) during maximal Valsalva strain:

• Points situated cranial/proximal to the hymen are assigned negative numbers; apical measurements may be more proximal than $-3$ cm.
• Points protruding distal/outside the hymen are assigned positive numbers ($0$ to $+tvl$ cm).

                               [ ANTERIOR WALL ]
                         Point Aa (-3 cm) │ Point Ba (-3 cm)
                                          │
                      [ GENITAL HIATUS ]  │  [ PERINEAL BODY ]
                             (gh)         │        (pb)
  ────────────────────────────────────────┼────────────────────────────────────────
                                     [ HYMEN ] (0)
  ────────────────────────────────────────┼────────────────────────────────────────
                        Point C (Cervix)  │ Point D (Post. Fornix)
                                          │
                         Point Ap (-3 cm) │ Point Bp (-3 cm)
                               [ POSTERIOR WALL ]
                               [ TOTAL LENGTH: tvl ]

POP-Q Landmark Points & Measurements

1. Point Aa: Anterior vaginal wall, midline, 3 cm proximal to the external urethral meatus (range: $-3$ to $+3$ cm).
2. Point Ba: Most dependent (distal) point of the remaining upper anterior vaginal wall from Point Aa to the anterior fornix (range: $-3$ to $+tvl$).
3. Point C: Most distal edge of the cervix or vaginal cuff scar (post-hysterectomy).
4. Point D: Posterior fornix (pouch of Douglas); represents apical uterosacral attachment. Omitted in women post-hysterectomy.
5. Point Ap: Posterior vaginal wall, midline, 3 cm proximal to the hymen (range: $-3$ to $+3$ cm).
6. Point Bp: Most dependent (distal) point of the upper posterior vaginal wall from Point Ap to the posterior fornix (range: $-3$ to $+tvl$).
7. Genital Hiatus (gh): Distance from the center of the external urethral meatus to the posterior midline hymen.
8. Perineal Body (pb): Distance from the posterior margin of the genital hiatus to the mid-anal orifice.
9. Total Vaginal Length (tvl): Maximum depth of the vagina when the apex is fully reduced.

POP-Q Staging Stages

• Stage 0: No prolapse. Points Aa, Ba, Ap, Bp are all at $-3$ cm, and Point C/D is $\le -(tvl - 2)$ cm.
• Stage I: The most distal aspect of the prolapse is $> 1$ cm above the hymenal ring (measurements $< -1$ cm).
• Stage II: The most distal aspect of the prolapse is located between $1$ cm above and $1$ cm below the hymen (measurements between $-1$ cm and $+1$ cm).
• Stage III: The leading edge is $>+1$ cm but $<+(tvl-2)$ cm. At $+(tvl-2)$ cm, classify as stageIV.
• Stage IV: Complete vaginal eversion / uterine procidentia (most distal point protrudes to $\ge +[tvl - 2]$ cm).

---

5. POP Management & Occult SUI Unmasking

Conservative Management

• Pessaries: Support pessaries (e.g., ring, ring with support) for Stages I–II; space-occupying pessaries (e.g., Gellhorn, cube) for Stages III–IV or a deficient perineal body. Fit individually, arrange removal/cleaning and follow-up, and discuss discharge, bleeding, expulsion and erosion. Consider vaginal oestrogen for associated menopausal atrophy; it is not mandatory for every pessary user. Supervised PFMT is also a conservative option for symptomatic POP.

Surgical Interventions

• Apical Prolapse Repair:
  • Sacrocolpopexy (Laparoscopic / Robotic / Open): Suspension of the vaginal cuff to the anterior longitudinal ligament of the sacral promontory using polypropylene mesh. Represents the gold standard for durable apical reconstruction.
  • Sacrospinous Ligament Fixation: Vaginal suspension of the apex to the sacrospinous ligament; avoids abdominal mesh, but carries risk of pudendal neurovascular injury and recurrent anterior prolapse.
• Anterior & Posterior Colporrhaphy: Native-tissue plication of attenuated pubocervical fascia (cystocele) or rectovaginal fascia (rectocele).

Occult Stress Urinary Incontinence (Unmasking Phenomenon)

• Mechanism: A large anterior prolapse (Stage III–IV cystocele) frequently causes mechanical kinking and compression of the urethra, artificially elevating urethral outflow resistance and masking underlying intrinsic sphincter deficiency or urethral hypermobility.
• Clinical Barrier Testing: The prolapse must be gently reduced using a pessary, Sims speculum, or swab while performing a cough stress test.
• Implication: If leakage is elicited upon reduction, the patient has occult (potential) SUI. The patient must be counseled regarding a staged anti-incontinence procedure versus a concomitant mid-urethral sling at the time of prolapse surgery.

---

6. Comparative Matrices: OAB, BPS & POP-Q Classification

OAB Stepped Management Matrix

Bladder Pain Syndrome (BPS/IC) Treatment Hierarchy Matrix

POP-Q Anatomical Landmarks Summary